Benjamin L. Maughan, MD, PharmD

Languages spoken: English
MyChart

Clinical Locations

  • Benjamin Maughan MD, PharmD is an Assistant Professor in the Division of Medical Oncology at Huntsman Cancer Institute specializing in genitourinary malignancies. Dr. Maughan completed his PharmD, cum laude, from Idaho State University in 2004, then completed an oncology pharmacy residency at Mountain States Tumor Institute in 2005. Dr. Maughan earned his MD, cum laude, from the University of Kentucky, College of Medicine in 2010. He finished his Internal Medicine residency training with the University of Utah in 2013 and subsequently completed his medical oncology fellowship at Johns Hopkins in 2016. He has been awarded the Huntsman Cancer Institute Translational Scholar Award in 2019, and was selected for the 2019 SWOG Young Investigator Training Course.

    Dr. Maughan has clinical and research interests in all genitourinary oncology, with a particular focus on the development of novel therapeutics and in identification of predictive biomarkers. During fellowship he studied predictive biomarkers in metastatic prostate cancer, specifically the role of truncated androgen receptors (AR-V7 expression) and loss of tumor suppressors (PTEN and Rb). More recently he is studying predictive biomarkers to immune therapy combinations in kidney, bladder and prostate cancers. He is exploring novel immune therapy combinations including checkpoint inhibitors combined with radiation therapy (radium-223), oncolytic viruses (MVA-brachyury) and targeted therapies (such as cabozantinib).

    He is the lead physician in a SWOG clinical trial exploring a novel treatment for patients with metastatic papillary kidney cancer.

    Board Certification and Academic Information

    Academic Departments Internal Medicine - Primary
    Academic Divisions Oncology

    Patient Rating

    4.9/5

    The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

    Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Learn more about our survey

    Patient Comments

    Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 23, 2022

    Dr Maughn is a wonderful doctor. Great listener and always spends as much time is needed during appt. I have never ever felt rushed I consider my care with Dr Maughn's team to be exceptional and consider myself very lucky

    October 21, 2022

    Provide written notes for the consultation

    September 04, 2022

    Absolutely recommend Dr Maughan and Lindsay to anyone with cancer.

    See More Patient Comments

  • Benjamin Maughan MD, PharmD is an Assistant Professor in the Division of Medical Oncology at Huntsman Cancer Institute specializing in genitourinary malignancies. Dr. Maughan completed his PharmD, cum laude, from Idaho State University in 2004, then completed an oncology pharmacy residency at Mountain States Tumor Institute in 2005. Dr. Maughan earned his MD, cum laude, from the University of Kentucky, College of Medicine in 2010. He finished his Internal Medicine residency training with the University of Utah in 2013 and subsequently completed his medical oncology fellowship at Johns Hopkins in 2016. He has been awarded the Huntsman Cancer Institute Translational Scholar Award in 2019, and was selected for the 2019 SWOG Young Investigator Training Course.

    Dr. Maughan has clinical and research interests in all genitourinary oncology, with a particular focus on the development of novel therapeutics and in identification of predictive biomarkers. During fellowship he studied predictive biomarkers in metastatic prostate cancer, specifically the role of truncated androgen receptors (AR-V7 expression) and loss of tumor suppressors (PTEN and Rb). More recently he is studying predictive biomarkers to immune therapy combinations in kidney, bladder and prostate cancers. He is exploring novel immune therapy combinations including checkpoint inhibitors combined with radiation therapy (radium-223), oncolytic viruses (MVA-brachyury) and targeted therapies (such as cabozantinib).

    He is the lead physician in a SWOG clinical trial exploring a novel treatment for patients with metastatic papillary kidney cancer.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology

    Research interests

    Education history

    Fellowship Medical Oncology - Johns Hopkins University Fellow
    Internal Medicine - University of Utah School of Medicine Resident
    Professional Medical Medicine - University of Kentucky College of Medicine M.D.
    Oncology Pharmacy - St. Luke's Mountain States Tumor Institute Resident
    Doctoral Training Pharmacy - Idaho State University College of Pharmacy Pharm.D.